Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression

Author(s): Liwei Lang, Austin Y. Shull, Yong Teng*.

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 1 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Coordination between the amplification of the fibroblast growth factor FGF19, overexpression of its corresponding receptor FGFR4, and hyperactivation of the downstream transmembrane enzyme β-klotho has been found to play pivotal roles in mediating tumor development and progression. Aberrant FGF19-FGFR4 signaling has been implicated in driving specific tumorigenic events including cancer cell proliferation, apoptosis resistance, and metastasis by activating a myriad of downstream signaling cascades. As an attractive target, several strategies implemented to disrupt the FGF19-FGFR4 axis have been developed in recent years, and FGF19-FGFR4 binding inhibitors are being intensely evaluated for their clinical use in treating FGF19-FGFR4 implicated cancers. Based on the established work, this review aims to detail how the FGF19-FGFR4 signaling pathway plays a vital role in cancer progression and why disrupting communication between FGF19 and FGFR4 serves as a promising therapeutic strategy for disrupting cancer progression.

Keywords: FGF19, FGFR4, β-klotho, cancer, target, drug development.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 1
Year: 2019
Page: [17 - 25]
Pages: 9
DOI: 10.2174/1568009618666180319091731
Price: $58

Article Metrics

PDF: 21